Debattenbeitrag: Krankenhausfinanzierung aus Sicht der Patienten

2021 ◽  
Vol 26 (11) ◽  
pp. 74-75
Author(s):  
Jörg Debatin ◽  
Heinz Lohmann

Das DRG-System berücksichtigt nicht den nachhaltigen Erfolg einer Behandlung aus Sicht des Patienten. Die Integration von „Patient Related Outcome Measures“ (PROM) sollte die Basis für eine Weiterentwick lung der DRGs hin zu neuen PRGs, also „Patient Related Groups“, sein. Das wäre ein mutiger Schritt nach vorn, der die Rolle der Patienten stärkt.

BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e047235
Author(s):  
Iona Pearson ◽  
Sue Blackwell ◽  
Rebecca Fish ◽  
Sarah Daniels ◽  
Malcolm West ◽  
...  

IntroductionPrehabilitation in colorectal surgery is evolving and may minimise postoperative morbidity and mortality. With many different healthcare professionals contributing to the prehabilitation literature, there is significant variation in reported primary endpoints that restricts comparison. In addition, there has been limited work on patient-related outcome measures suggesting that patients with colorectal cancer needs and issues are being overlooked. The Defining Standards in Colorectal Optimisation Study aims to achieve international consensus from all stakeholders on key standards to provide a framework for reporting future prehabilitation research.Methods and analysisA systematic review will identify key standards reported in trials of prehabilitation in colorectal surgery. Standards that are important to patients will be identified by a patient and public involvement (PPI) event. The longlist of standards generated from the systematic review and PPI event will be used to develop a three-round online Delphi process. This will engage all stakeholders (healthcare professionals and patients) both nationally and internationally. The results of the Delphi will be followed by a face-to-face interactive consensus meeting that will define the final standards for prehabilitation for elective colorectal surgery.Ethics and disseminationThe University of Glasgow College of Medical, Veterinary and Life Sciences Ethics Committee has approved this protocol, which is registered as a study (200190120) with the Core Outcome Measures in Effectiveness Trials Initiative. Publication of the standards developed by all stakeholders will increase the potential for comparative research that advances understanding of the clinical application of prehabilitation.PROSPERO registration numberCRD42019120381.


2019 ◽  
Vol 4 (4) ◽  
pp. 2473011419S0002
Author(s):  
Alastair Faulkner ◽  
Alistair Mayne ◽  
Fraser Harrold

Category: Midfoot/Forefoot Introduction/Purpose: Morton’s neuroma is a common condition affecting the foot and is associated with chronic pain and disability. Conservative management including a combination of orthotic input; injection or physiotherapy, and surgical excision are current treatment options. There is a paucity of literature regarding patient related outcome measures (PROMs) data in patients managed conservatively. We sought to compare conservative with surgical management of Morton’s neuroma using PROMs data in patients with follow-up to one year. Methods: Prospective data collection commenced from April 2016. Patients included had to have a confirmed Morton’s neuroma on ultrasound scan. Patient demographics including age, sex and BMI were collected. The primary outcome measures were the Manchester Foot Score for pain (MOX-FQ), EQ time trade off (TTO) and EQ visual analogue scale (VAS) taken pre-operatively; at 26-weeks and at 52-weeks post-operatively. Results: 194 patients were included overall: 79 patients were conservatively managed and 115 surgically managed. 19 patients were converted from conservative to surgical management. MOX-FQ pain scores: pre-op conservative 52.15, surgical 61.56 (p=0.009), 6-months conservative 25.1, surgical 25.39 (p=0.810), 12 months conservative 18.54, surgical 20.52 (p=0.482) EQ-TTO scores: pre-op conservative 0.47, surgical 0.51 (p=0.814), 6-months conservative 0.41, surgical 0.49 (p=0.261), 12 months conservative 0.26, surgical 0.37 (p=0.047) EQ-VAS scores: pre-op conservative 63.84, surgical 71.03 (p=0.172), 6-months conservative 46.10, surgical 52.51 (p=0.337), 12 months conservative 30.77, surgical 37.58 (p=0.227) Satisfaction at 12 months: conservative 17 (21.5%), surgical 32 (27.8%) p=0.327 Conclusion: This is one of the first studies investigating long-term PROMs specifically in conservative management for Morton’s neuroma patients. There was no significant difference in pain score and EQ-VAS between all conservative treatments and surgical management at 12 months There was no significant difference in satisfaction at 12 months between conservative and surgical groups.


2018 ◽  
Vol 275 (5) ◽  
pp. 1039-1048 ◽  
Author(s):  
Chi Lap Nicholas Tsang ◽  
Theresa Nguyen ◽  
Torunn Sivesind ◽  
Anders Cervin

2020 ◽  
pp. 107110072096106
Author(s):  
Alastair Faulkner ◽  
Alistair Mayne ◽  
Peter Davies ◽  
David Ridley ◽  
Fraser Harrold

Background: Morton’s neuroma is associated with chronic pain and disability. There is a paucity of literature regarding patient-related outcome measures (PROMs) in patients managed nonoperatively. We sought to investigate nonoperative and operative management of Morton’s neuroma using PROMs in patients with follow-up to 1 year. Methods: We conducted a prospective observational study and collected data on all patients with a new diagnosis of Morton’s neuroma treated from February 2016 until April 2018. Primary outcome measures were the Manchester-Oxford Foot Questionnaire (MOXFQ) for pain, EuroQoL (EQ) time trade-off (TTO), and EQ visual analog scale (VAS) taken preoperatively and at 52 weeks postoperatively. Forty-four patients were treated nonoperatively and 94 patients were treated operatively. Results: Pretreatment and 52-week scores were 55.7 and 43.10 (nonoperative) and 63.7 and 40.1 (operative) for MOXFQ (pain), 0.72 and 0.82 (nonoperative) and 0.68 and 0.82 (operative) for EQ-TTO, and 71.5 and 76.2 (nonoperative) and 73.1 and 68.7 (operative) for EQ-VAS. There was a statistically significant improvement in MOXFQ (pain) in nonoperative ( P = .02) and operative groups ( P < .001). There was a statistically significant improvement in EQ-TTO in the operative group only ( P = .01). Conclusion: This is the largest study investigating outcomes to 12 months of both nonoperative and operatively managed patients with Morton’s neuroma. Both nonoperative and operative management lead to symptom improvement at 12 months. Level of Evidence: Level III, comparative study.


2013 ◽  
Vol 33 (11) ◽  
pp. 2731-2736 ◽  
Author(s):  
Rafael Ariza-Ariza ◽  
Blanca Hernández-Cruz ◽  
Victoria Navarro-Compán ◽  
Christian Leyva Pardo ◽  
Xavier Juanola ◽  
...  

Author(s):  
Alberto Cauli

In order to define and validate standardized outcome measurement tools both for therapeutic trials and for real life clinics, the need to precisely identify the relevant domains of psoriasis and psoriatic arthritis has led to the ‘rassemblement’ of experts and patients in the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The output of intensive work, performed according to the Outcome Measures in Rheumatology (OMERACT) scientific method, has been the definition of the key domains and instruments relevant in PsA evaluation. This chapter summarizes the present approach in PsA assessment, focusing on the ‘pathophysiological manifestations’, as well as current ideas regarding future revisions. Patient-related outcome measures and composite scores will be detailed in other chapters.


Gland Surgery ◽  
2019 ◽  
Vol 8 (4) ◽  
pp. 425-430
Author(s):  
Daniel C. Williams ◽  
Marc A. Seifman ◽  
David J. Hunter-Smith

Sign in / Sign up

Export Citation Format

Share Document